Featured Research

from universities, journals, and other organizations

Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web

Date:
May 6, 1999
Source:
National Institute Of Allergy And Infectious Diseases
Summary:
An updated version of the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents has been posted to the AIDS Treatment Information Service Web site, www.hivatis.org. The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection.

The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection, a joint effort of the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. The Guidelines were constructed as a "living document" and are updated frequently by the Panel.

"We feel that the Guidelines are an invaluable resource to all health care providers who care for HIV-infected individuals," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and co-chair of the Panel. The Guidelines were published in hard-copy form in the Morbidity and Mortality Weekly Report and in the Annals of Internal Medicine in 1998; however, they are updated frequently on the ATIS Web site. In addition, a hard copy of the most recent version of the Guidelines can be obtained for free by calling 1-800-448-0440.

Included in the latest version of the Guidelines are recommendations for the use of the recently approved anti-HIV drug abacavir (trade name Ziagen). Abacavir is a potent anti-HIV agent belonging to a class of drugs known as nucleoside analog reverse transcriptase inhibitors. This family of drugs also includes zidovudine (AZT) and lamivudine (3TC).

Clinical trials of abacavir combined with AZT and 3TC have shown that this combination suppresses HIV replication and boosts CD4+ T-cell counts to a degree comparable to widely used treatment regimens that combine a protease inhibitor drug with AZT and 3TC. CD4+ T cells are the crucial immune system cells depleted during the course of HIV disease.

The Panel notes that the potential advantages of the abacavir+AZT+3TC regimen include ease of administration (two pills twice daily), and the opportunity to save other classes of potent anti-HIV drugs, some with a higher incidence of undesirable side effects, for later use.

However, "The Panel is concerned about the ability of the abacavir+AZT+3TC regimen to adequately suppress HIV replication in individuals with high baseline levels of plasma viral load," says John G. Bartlett, M.D., chief of the division of infectious diseases at the Johns Hopkins University Medical Center and co-chair of the Panel.

In addition, abacavir has been associated with a hypersensitivity syndrome that can be life-threatening. In clinical trials, the hypersensitivity syndrome associated with abacavir occurred in approximately 5 percent of patients. In cases where the drug was discontinued because of hypersensitivity reactions and then re-introduced, life-threatening exacerbations of the hypersensitivity syndrome occurred. A medication guide and warning card providing information about recognizing the abacavir hypersensitivity syndrome should be dispensed with each abacavir prescription.

Currently, the Panel recommends using the abacavir-containing regimen as an "alternative" to the preferred regimens delineated in the Guidelines, which include two nucleoside analog reverse transcriptase inhibitors in combination with either a protease inhibitor or efavirenz, a non-nucleoside reverse transcriptase inhibitor.

The Panel also considered recently published data suggesting that HIV-infected women experience more rapid disease progression compared with men who have the same level of virus in their bloodstream. These data were obtained in studies of women who were injecting drug users, and the results have not been consistently observed in other studies. The Panel therefore did not recommend that women begin antiretroviral therapy earlier than men, but will continue to closely follow developments in this field.

The revised Guidelines also include a hypertext link to a brief discussion of the controversy surrounding the use of the drug hydroxyurea in the treatment of HIV infection. In addition, tables and charts in the Guidelines have been updated and reorganized in a more user-friendly way.

In the near future, the Panel will issue an additional update to the Guidelines delineating its recommendations regarding the use of the recently approved protease inhibitor, amprenavir (Agenerase).

Co-conveners of the Panel on Clinical Practices for the Treatment of HIV Infection are Eric Goosby, M.D., on behalf of the Department of Health and Human Services, and Sophia Chang, M.D., on behalf of the Henry J. Kaiser Family Foundation.

NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.

The Henry J. Kaiser Family Foundation, based in Menlo Park, Calif., is an independent health care philanthropy and is not associated with Kaiser Permanente or Kaiser Industries.

###

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.


Story Source:

The above story is based on materials provided by National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

National Institute Of Allergy And Infectious Diseases. "Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web." ScienceDaily. ScienceDaily, 6 May 1999. <www.sciencedaily.com/releases/1999/05/990505161644.htm>.
National Institute Of Allergy And Infectious Diseases. (1999, May 6). Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1999/05/990505161644.htm
National Institute Of Allergy And Infectious Diseases. "Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web." ScienceDaily. www.sciencedaily.com/releases/1999/05/990505161644.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins